RT Journal Article
SR Electronic
T1 Therapeutic targeting of metabolic alterations in acute respiratory distress syndrome
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 200114
DO 10.1183/16000617.0114-2020
VO 29
IS 156
A1 Matthew John Robinson
A1 Anna D. Krasnodembskaya
YR 2020
UL http://err.ersjournals.com/content/29/156/200114.abstract
AB Acute respiratory distress syndrome (ARDS) remains a significant source of mortality in critically ill patients. Characterised by acute, widespread alveolar inflammation and pulmonary oedema, its pathophysiological heterogeneity has meant that targeted treatments have remained elusive. Metabolomic analysis has made initial steps in characterising the underlying metabolic derangements of ARDS as an indicator of phenotypical class and has identified mitochondrial dysfunction as a potential therapeutic target. Mesenchymal stem cells and their derived extracellular vesicles have shown significant promise as potential therapies in delivering mitochondria in order to redivert metabolism onto physiological pathways.ARDS' biological heterogeneity is an obstacle in clinical translation of interventions. Analysis of metabolic alterations can inform development of therapeutics aimed at ARDS subpopulations. Mitochondrial dysfunction may be a potential therapeutic target. https://bit.ly/2XHfAFV